From palliative to curative treatment - stage IV mucinous adenocarcinoma, successfully treated with metronomic capecitabine in combination with Bevacizumab and surgery- a case report
2015 (English)In: BMC Cancer, ISSN 1471-2407, E-ISSN 1471-2407, Vol. 15, no 884Article in journal (Refereed) PublishedText
Background: Mucinous adenocarcinoma (MAC) represents 6-19 % of all colorectal carcinoma. It is associated with poorer response to chemotherapy and chemoradiotherapy. Case presentation: A 27-year-old Swedish woman presented with stomach pain and weight loss, and was diagnosed with locally advanced MAC in the transverse colon as well as 3 liver metastases. Neoadjuvant treatment with fluorouracil, folinic acid and oxaliplatin (FLOX) failed due to several infections, pulmonary embolism and deteriorated performance status. The patient was therefore considered palliative. Palliative treatment with metronomic capecitabine 500 mg x 2 daily and bevacizumab every other week were initiated. After 4 months of treatment the tumors had regressed and the patient was able to undergo radical surgery, thereby changing the treatment intention from palliative to curative. No adjuvant chemotherapy was given. There were no signs of recurrence 9 months later. Conclusions: The role of the combination of metronomic capecitabine and bevacizumab in patients with MAC merits further investigation.
Place, publisher, year, edition, pages
BIOMED CENTRAL LTD , 2015. Vol. 15, no 884
Mucinous adenocarcinoma; Bevaczumab; Metronomic capecitabine
IdentifiersURN: urn:nbn:se:liu:diva-123523DOI: 10.1186/s12885-015-1908-3ISI: 000365272200003PubMedID: 26555668OAI: oai:DiVA.org:liu-123523DiVA: diva2:886263
Funding Agencies|foundation of Oncological Clinical Research in Linkoping2015-12-222015-12-212016-04-12